Canada - Tiếng Anh - Health Canada

insight pharmaceuticals, llc - fluconazole - capsule - 150mg - fluconazole 150mg - azoles

Canada - Tiếng Anh - Health Canada

insight pharmaceuticals, llc - fluconazole; miconazole nitrate - kit - 150mg; 2% - fluconazole 150mg; miconazole nitrate 2% - azoles

Canada - Tiếng Anh - Health Canada

wellspring pharmaceutical canada corp - miconazole nitrate - cream - 2% - miconazole nitrate 2% - azoles

Canada - Tiếng Anh - Health Canada

wellspring pharmaceutical canada corp - miconazole nitrate - aerosol - 2% - miconazole nitrate 2% - azoles

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

alcon laboratories, inc. - natamycin (unii: 8o0c852cpo) (natamycin - unii:8o0c852cpo) - natacyn® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including fusarium solani keratitis. as in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. the effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. natacyn® (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

eyevance pharmaceuticals, llc - natamycin (unii: 8o0c852cpo) (natamycin - unii:8o0c852cpo) - natacyn ® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including fusarium solani keratitis. as in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. the effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. natacyn ® (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed be